The basic principles of managing the patients with impaired tone after focal brain damage

  • Authors: Khatkova S.E1,2, Orlova O.R3, Botsina A.Y.4, Shikhkerimov R.K5, Kovalenko A.P6
  • Affiliations:
    1. Treatment and Rehabilitation Center of the Ministry of Health of the Russian Federation
    2. A.I.Burnazyan Federal Medical Biophysical Center FMBA of Russia
    3. I.M.Sechenov First Moscow Medical University of the Ministry of Health of the Russian Federation
    4. I.V.Davydovskiy City Clinical Hospital of the Department of Health of Moscow
    5. Ambulance unit of Polyclinic №166 of the Department of Health of Moscow
    6. S.M.Kirov Military Medical Academy
  • Issue: Vol 18, No 2.1 (2016)
  • Pages: 25-33
  • Section: Articles
  • URL: https://journals.rcsi.science/2075-1753/article/view/95157
  • ID: 95157

Cite item

Full Text

Abstract

According to current data, not less than 1/3 of patients with focal brain injury, stroke, or traumatic brain injury, early in the recovery period of the disease is formed by focal or multifocal spasticity. This syndrome is significantly impairs vital functions of patients, limiting active and passive limb motor function, the possibility of rehabilitation, causing pain. Today, the specific treatment for focal or multifocal spasticity having a high level and the class of evidence is Botulinum, which is a regular injection of botulinum toxin type A into the muscles that shape an individual spastic pattern. Botulinum should be included in the complex of programs for the rehabilitation of patients with focal brain damage.

About the authors

S. E Khatkova

Treatment and Rehabilitation Center of the Ministry of Health of the Russian Federation; A.I.Burnazyan Federal Medical Biophysical Center FMBA of Russia

Email: hse15@mail.ru
д-р мед. наук, проф. каф. восстановительной медицины, спортивной медицины, курортологии и физиотерапии с курсом сестринского дела ФГБУ ГНЦ ФМБЦ им. А.И.Бурназяна, зав. отд. неврологии для БНМК; ФГАУ ЛРЦ 125367, Russian Federation, Moscow, Ivan'kovskoe shosse, d. 3

O. R Orlova

I.M.Sechenov First Moscow Medical University of the Ministry of Health of the Russian Federation

Email: ororlova@yandex.ru
д-р мед. наук, проф. каф. нервных болезней ИПО ГБОУ ВПО Первый МГМУ им. И.М.Сеченова; президент Межрегиональной общественной организации специалистов ботулинотерапии (МООСБТ); рук. неврологического отд-ния ЦМСиН 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2

A. Yu Botsina

I.V.Davydovskiy City Clinical Hospital of the Department of Health of Moscow

Email: abotsina@gmail.com
канд. мед. наук, зав. отд-нием для больных с ОНМК ГБУЗ ГКБ им. И.В.Давыдовского 109240, Russian Federation, Moscow, ul. Yauzskaya, d. 11

R. K Shikhkerimov

Ambulance unit of Polyclinic №166 of the Department of Health of Moscow

Email: rodoss72@gmail.com
д-р мед. наук, зав. неврологическим отд-нием ГБУЗ ГП №166, гл. невролог ЮАО г. Москвы 115551, Russian Federation, Moscow, Domodedovskaya ul., d. 9

A. P Kovalenko

S.M.Kirov Military Medical Academy

Email: kvlnko73@gmail.com
канд. мед. наук, доц. каф. нервных болезней, гл. реабилитолог ФГБВОУ ВПО ВМА им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6

References

  1. Куликов А.Ю., Угрехелидзе Д.Т. Фармакоэкономическое исследование применения препаратов ботулинического токсина при терапии постинсультной спастичности верхней конечности. Фармакоэкономика. Теория и практика. 2014; 2 (3): 28-37.
  2. Орлова О.Р., Тимербаева С.Л., Хатькова С.Е. и др. Ботулинотерапия в клинической практике. В кн.: Голубев В.Л. Избранные лекции по неврологии. II. М.: МЕДпресс - информ, 2012; с. 81-103.
  3. Триумфов А.В. Топическая диагностика заболеваний нервной системы. Л.: МЕДГИЗ, 1959.
  4. Хатькова С.Е., Конева Е.С., Сидякина И.В. Комплексная реабилитация больных с постинсультной спастичностью руки. Практическое руководство для врачей. М.: ФГБУ «Лечебно - реабилитационный центр», 2011.
  5. Хатькова С.Е., Орлова О.Р., Тимербаева С.Л., Познякова Е.В. Оценка клинического профиля пациентов со спастичностью верхней конечности, которым показаны инъекции ботулинического токсина типа А (по данным международного исследования). Журн. неврологии и психиатрии им. С.С.Корсакова, 2011; 111 (8): 23-6.
  6. Шабалов В.А., Декопов А.В., Томский А.А., Салова Е.М. Задняя селективная ризотомия в лечении тяжелого спастического синдрома при ДЦП. Вопр. нейрохирургии им. Н.Н.Бурденко. 2010; 74 (2): 14-8.
  7. Шихкеримов Р.К. Актуальность пациент - ориентированного подхода в реабилитации больных с постинсультной спастичностью. В кн.: Болезни мозга - медицинские и социальные аспекты. 2016; с. 147-64.
  8. Anakwenze O.A, Namdari S, Hsu J.E et al. Myotendinous lengthening of the elbow flexor muscles to improve active motion in patients with elbow spasticity following brain injury. J Shoulder Elbow Surg 2013; 22 (3): 318-22.
  9. Bakheit A.M, Fedorova N.V, Skoromets A.A et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004; 75 (11): 1558-61.
  10. Barnes M.P, Johnson G.R. UMN syndrome and spasticity. Cambridge University Press 2008.
  11. Brown M, Levack W, Mc Pherson K.M et al. Survival, momentum, and things that make me "me": patients' perceptions of goal setting after stroke. Disabil Rehabil 2014; 36 (12): 1020-6.
  12. Chen J.C, Shaw F.Z. Progress in sensorimotor rehabilitative physical therapy programs for stroke patients. World J Clin Cases 2014; 2 (8): 316-26.
  13. Dimitrijevic M.M, Dimitrijevic M.R, Illis L.S et al. Spinal cord stimulation for the control of spasticity in patients with chronic spinal cord injury: I. Clinical observations. Cent Nerv Syst Trauma 1986; 3 (2): 129-44.
  14. Doan Q.V, Gillard P, Brashear A et al. Cost - effectiveness of on a botulinumtoxin A for the treatment of wrist and hand disability due to upper - limb post - stroke spasticity in Scotland. Eur J Neurol 2013; 20 (5): 773-80.
  15. Etoom M, Hawamdeh M, Hawamdeh Z et al. Constraint - induced movement therapy as a rehabilitation intervention for upper extremity in stroke patients: systematic review and meta - analysis. Int J Rehabil Res 2016.
  16. Foley N, Murie-Fernandez M, Speechley M et al. Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta - analysis. Eur J Neurol 2010; 17 (12): 1419-27.
  17. Francisco G.E, Boake C. Improvement in walking speed in poststroke spastic hemiplegia after intrathecal baclofen therapy: a preliminary study. Arch Phys Med Rehabil 2003; 84 (8): 1194-9.
  18. Francisco G.E, Yablon S.A, Schiess M.C et al. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil 2006; 13 (4): 74-85.
  19. Gracies J.M. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes. Muscle Nerve 2005; 31 (5): 535-51.
  20. Gracies J.M. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity. Muscle Nerve 2005; 31 (5): 552-71.
  21. Gracies J.M. Coefficients of impairment in deforming spastic paresis. Ann Phys Rehabil Med 2015; 58 (3): 173-8.
  22. Gracies J.M, Bayle N, Vinti M et al. Five - step clinical assessment in spastic paresis. Eur J Phys Rehabil Med 2010; 46 (3): 411-21.
  23. Gracies J.M, Brashear A, Jech R et al. Safety and efficacy of abobotulinumtoxin A for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double - blind randomised controlled trial. Lancet Neurol 2015; 14 (10): 992-1001.
  24. Graham L.A. Management of spasticity revisited. Age Ageing 2013; 42 (4): 435-41.
  25. Hesse S, Mach H, Frohlich S et al. An early botulinum toxin A treatment in subacute stroke patients may prevent a disabling finger flexor stiffness six months later: a randomized controlled trial. Clin Rehabil 2012; 26 (3): 237-45.
  26. Hesse S, Reiter F, Konrad M, Jahnke M.T. Botulinum toxin type A and short - term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double - blind, placebo - controlled trial. Clin Rehabil 1998; 12 (5): 381-8.
  27. Horn T.S, Yablon S.A, Stokic D.S. Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury. Arch Phys Med Rehabil 2005; 86 (6): 1127-33.
  28. Ivanhoe C.B, Francisco G.E, Mc Guire J.R et al. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil 2006; 87 (11): 1509-15.
  29. Kaji R, Osako Y, Suyama K et al. Botulinum toxin type A in post - stroke lower limb spasticity: a multicenter, double - blind, placebo - controlled trial. J Neurol 2010; 257 (8): 1330-7.
  30. Kakuda W, Abo M, Momosaki R et al. Combined therapeutic application of botulinum toxin type A, low - frequency rTMS, and intensive occupational therapy for post - stroke spastic upper limb hemiparesis. Eur J Phys Rehabil Med 2012; 48 (1): 47-55.
  31. Kakuda W, Abo M, Shimizu M et al. A multi - center study on low - frequency rTMS combined with intensive occupational therapy for upper limb hemiparesis in post - stroke patients. J Neuroeng Rehabil 2012; 9 (1): 4.
  32. Katrak P.H, Cole A.M, Poulos C.J, Mc Cauley J.C. Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double - blind study. Arch Phys Med Rehabil 1992; 73 (1): 4-9.
  33. Khalil N, Hutin E, Santiago T et al. Guided self - rehabilitation contracts and gait speed in chronic hemiparesis. A prospective study. Ann Phys Rehabil Med 2013; 56 (Suppl. 1): e45-e46.
  34. Lam K, Lau K.K, So K.K et al. Can botulinum toxin decrease carer burden in long term care residents with upper limb spasticity? A randomized controlled study. J Am Med Dir Assoc 2012; 13 (5): 477-84.
  35. Lance J. Symposium synopsis in spasticity; in Disordered motor control., Feldman R, Young R, Koella W, Editors. 1980, IL: Year Book Medical Publishers: Chicago; p. 487-9.
  36. Lance J.W. Symposium synopsis, in Spasticity: Disordered Motor Control., Feldman R.G, Young R.R, Koella W.P, Editors. 1980, IL: Yearbook Medical: Chicago; p. 485-94.
  37. Leathley M.J, Gregson J.M, Moore A.P et al. Predicting spasticity after stroke in those surviving to 12 months. Clin Rehabil 2004; 18 (4): 438-43.
  38. Lundstrom E, Smits A, Borg J, Terent A. Four - fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010; 41 (2): 319-24.
  39. Lundstrom E, Smits A, Terent A, Borg J. Time - course and determinants of spasticity during the first six months following first - ever stroke. J Rehabil Med 2010; 42 (4): 296-301.
  40. Lundstrom E, Terent A, Borg J. Prevalence of disabling spasticity 1 year after first - ever stroke. Eur J Neurol 2008; 15 (6): 533-9.
  41. Mayer N.H. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 1997; 6: S1-13.
  42. Meythaler J.M, De Vivo M.J, Hadley M. Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil 1996; 77 (5): 461-6.
  43. Namdari S, Alosh H, Baldwin K et al. Outcomes of tendon fractional lengthenings to improve shoulder function in patients with spastic hemiparesis. J Shoulder Elbow Surg 2012; 21 (5): 691-8.
  44. Olvey E.L, Armstrong E.P, Grizzle A.J. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther 2010; 32 (14): 2282-303.
  45. Peacock W.J, Staudt L.A. Functional outcomes following selective posterior rhizotomy in children with cerebral palsy. J Neurosurg 1991; 74 (3): 380-5.
  46. Pittock S.J, Moore A.P, Hardiman O et al. A double - blind randomised placebo - controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003; 15 (4): 289-300.
  47. Price C.I, Pandyan A.D. Electrical stimulation for preventing and treating post - stroke shoulder pain: a systematic Cochrane review. Clin Rehabil 2001; 15 (1): 5-19.
  48. Remy-Neris O, Tiffreau V, Bouilland S, Bussel B. Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. Arch Phys Med Rehabil 2003; 84 (5): 643-50.
  49. Rosales R.L, Kong K.H, Goh K.J et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair 2012; 26 (7): 812-21.
  50. Rousseaux M, Buisset N, Daveluy W et al. Long - term effect of tibial nerve neurotomy in stroke patients with lower limb spasticity. J Neurol Sci 2009; 278 (1-2): 71-6.
  51. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Neurology A.o.C.P.I.i., Spasticity in adults: management using botulinum toxin. National Guidelines 2009, London: RCP.
  52. Santamato A, Micello M.F, Panza F et al. Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of pos t -stroke lower limb spasticity: a prospective open - label study. Eur J Phys Rehabil Med 2013; 49 (4): 483-9.
  53. Sheean G. The pathophysiology of spasticity. Eur J Neurol 2002 (9 Suppl. 1): 3-9; discussion 53-61.
  54. Sheean G. The neurophysiology of spasticity., in Upper Motor Neurone Syndrome and Spasticity., Barnes M.P, Johnson G.R, Editors. 2008, NY: Cambridge University Press: New York; p. 9-63.
  55. Sherrington C.S. The Integrative Action of the Nervous System. 1947, New Haven: CT: Yale University Press.
  56. Simpson D.M, Gracies J.M, Yablon S.A et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo - controlled study. J Neurol Neurosurg Psychiatry 2009; 80 (4): 380-5.
  57. Simpson D.M, Hallett M, Ashman E.J et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016; 86 (19): 1818-26.
  58. Sommerfeld D.K, Eek E.U, Svensson A.K et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 2004; 35 (1): 134-9.
  59. Tardieu C, Huet de la Tour E, Bret M.D, Tardieu G. Muscle hypoextensibility in children with cerebral palsy: I. Clinical and experimental observations. Arch Phys Med Rehabil 1982; 63 (3): 97-102.
  60. Tardieu G. Les feuillets de l’infirmité motrice cérébrale; in Evaluation et caractères distinctifs des diverses raideurs d’origine cérébrale. Association Nationale des IMC Ed.: Paris 1966; p. 1-28.
  61. Tardieu G, Lacert P. Le tonus et ses troubles en clinique. Encyclopédie medico - chirurgicale. Paris: Neurologie, 1977.
  62. Tardieu G, Shentoub S, Delarue R. A la recherche d'une technique de mesure de la spasticite. Rev Neurol (Paris) 1954; 91 (2): 143-4.
  63. Teasell R, Foley N, Salter K et al. Evidence-Based Review of Stroke Rehabilitation: executive summary, 16th edition. 2013; Available from: http://www.ebrsr.com/ [Accessed 17.03.2014 2014].
  64. Thieme H, Mehrholz J, Pohl M et al. Mirror therapy for improving motor function after stroke. Stroke 2013; 44 (1): e1-2.
  65. Tok F, Balaban B, Yasar E et al. The effects of onabotulinum toxin A injection into rectus femoris muscle in hemiplegic stroke patients with stiff - knee gait: a placebo - controlled, nonrandomized trial. Am J Phys Med Rehabil 2012; 91 (4): 321-6.
  66. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULISII):a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real - life clinical management. BMJ Open 2013; 3 (6).
  67. Urban P.P., Wolf T, Uebele et al. Occurence and clinical predictors of spasticity after ischemic stroke. Stroke 2010; 41 (9): 2016-20.
  68. Welmer A.K, Widen Holmqvist L, Sommerfeld D.K. Location and severity of spasticity in the first 1-2 weeks and at 3 and 18 months after stroke. Eur J Neurol 2010; 17 (5): 720-5.
  69. Whitlock J.A. Neurophysiology of spasticity; in The Practical Management of Spasticity in Children and Adults, Glen M.B, Whyte J, Editors. 1990, PA: Lea & Febiger: Philadelphia; p. 8-33.
  70. Winstein C.J, Stein J, Arena R et al. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2016.
  71. Wissel J, Schelosky L.D, Scott J et al. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010; 257 (7): 1067-72.
  72. Wissel J, Verrier M, Simpson D.M et al. Post - stroke spasticity: predictors of early development and considerations for therapeutic intervention. PM R 2015; 7 (1): 60-7.
  73. Wissel J, Ward A.B, Erztgaard P et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009; 41 (1): 13-25.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies